

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

This document gives notice of the Feedback plc 2022 Annual General Meeting and sets out resolutions to be voted on at the meeting. If you are in any doubt as to the action you should take, it is recommended that you seek your own advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent professional adviser authorised under the Financial Services and Markets Act 2000 if you are resident in the United Kingdom or, if not, from another appropriately authorised independent professional adviser.

If you sell or have sold or otherwise transferred all your ordinary shares in Feedback plc (“Ordinary Shares”), you should send this document together with the accompanying documents at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for onward transmission to the purchaser or transferee. If you sell or have sold only part of your holding of Ordinary Shares, you should retain this document and the accompanying documents and consult the bank, stockbroker or other agent through whom the sale or transfer was effected.



Feedback plc

(Incorporated in England and Wales with registered number 00598696)

Notice of 2022 Annual General Meeting

The 2022 Annual General Meeting (“AGM”) of Feedback plc will be held at Temple Chambers, 1-3 Temple Avenue, London, EC4Y 0DT, on Thursday 13 October 2022 at 11:00 a.m.

Whether or not you propose to attend the AGM, please complete and submit a proxy appointment form or electronic proxy appointment instruction in accordance with the Notes to the Notice of the AGM set out on pages 8 – 9. To be valid, the Form of Proxy (“Form of Proxy”) or electronic proxy instruction must be received at the address for delivery specified in the notes by 11:00 a.m. on 11 October 2022.

Proposed Share Consolidation

Feedback plc is proposing to conduct a share consolidation and a resolution to this effect will be proposed to shareholders at the AGM.

Further information on the proposed share consolidation is set out in the Explanatory Notes to the Notice of AGM on pages 4 – 7.

Indicative Timetable of Principal Events

Publication and posting of Notice of AGM	20 September 2022
Latest time and date for return of Form of Proxy for AGM	11.00 a.m. on 11 October 2022
AGM	11.00 a.m. on 13 October 2022
Announcement of the result of the AGM	13 October 2022
Record Date and final date for trading in Existing Ordinary Shares	6.00 p.m. on 13 October 2022
Expected Admission to trading on AIM of the Consolidated Ordinary Shares arising from the Consolidation	8.00 a.m. on 14 October 2022

Notice of Annual General Meeting

Feedback plc

(Registered in England and Wales with Company number 00598696)

Notice is hereby given that the Annual General Meeting (“AGM”) of the members of Feedback plc (the “Company”) (“Group”) will be held at Temple Chambers, 1-3 Temple Avenue, London, EC4Y 0DT, on Thursday 13 October 2022 at 11:00 a.m. for the purpose of considering and, if thought fit, passing the following resolutions. Resolutions 1 to 8 (inclusive) and Resolution 10 are proposed as ordinary resolutions and Resolutions 9 and 11 are proposed as special resolutions.

Ordinary Business

As ordinary resolutions:

1. To receive and adopt the Company’s annual accounts for the year ended 31 May 2022 together with the Directors’ report and the Auditors’ report thereon.
2. To receive and approve the report on Directors’ remuneration for the year ended 31 May 2022.
3. To re-appoint Price Bailey LLP as Auditor of the Company to hold office until the conclusion of the next annual general meeting at which accounts are laid before the members.
4. To authorise the Directors to determine the fees payable to the Auditor.
5. To elect Anesh Patel as a Director of the Company pursuant to the articles of association of the Company.
6. To elect Annemijn Eschauzier as a Director of the Company pursuant to the articles of association of the Company.
7. To re-elect Rory Shaw as a Director of the Company, who retires pursuant to the articles of association of the Company.

Special Business

8. As an ordinary resolution:

That the Directors be and are hereby generally and unconditionally authorised pursuant to and in accordance with section 551 of the Companies Act 2006 (as amended) (the “Act”) to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company (such shares and such rights to subscribe for or to convert any security into shares in the Company being “Equity Securities”) to such persons on such terms and in such manner as they shall think fit, provided that this authority shall be limited to the allotment of Equity Securities up to a maximum aggregate nominal amount of £2,220,220.62, being approximately 33.3% of the aggregate nominal value of the Company’s issued ordinary share capital as at the date hereof, at any time during the period from the date hereof until the conclusion of the next Annual General Meeting of the Company or fifteen months after the passing of this resolution, whichever is earlier (unless and to the extent previously renewed, revoked or varied by the Company in a general meeting), provided that the Directors may make an offer or enter into an agreement which would or might require equity securities to be allotted, offered or otherwise dealt with or disposed of after the expiry of such authority and the Directors may allot any equity securities after the expiry of such authority in pursuance of any such offer or agreement as if this authority had not expired.

9. As a special resolution:

To resolve that the Directors be empowered pursuant to section 570 of the Companies Act 2006 to allot equity securities (as defined in section 560 of that Act) for cash pursuant to the general authority conferred on them by resolution 8 and/or to sell equity securities held as treasury shares for cash pursuant to section 727 of the Companies Act 2006, in each case as if section 561 of that Act did not apply to any such allotment or sale, provided that this power shall be limited to:

- (a) any such allotment and/or sale of equity securities in connection with an offer or issue by way of rights or other pre-emptive offer or issue, open for acceptance for a period fixed by the Directors, to holders of ordinary shares (other than the Company) on the register on any record date fixed by the Directors in proportion (as nearly as may be) to the respective number of ordinary shares deemed to be held by them, subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, legal or practical problems arising in any overseas territory, the requirements of any regulatory body or stock exchange or any other matter whatsoever; and
- (b) any such allotment and/or sale, otherwise than pursuant to paragraph (a) above, of equity securities having, in the case of ordinary shares, an aggregate nominal value or, in the case of other equity securities, giving the right to subscribe for or convert into ordinary shares having an aggregate nominal value, not exceeding £666,732.92.

This authority shall expire (unless previously varied as to duration, revoked or renewed by the Company in a general meeting) on the date that is fifteen months from the date of the Annual General Meeting or, if earlier, at the conclusion of the Annual General Meeting of the Company in 2023, save that the Company may before such expiry make any offer or agreement which would or might require equity securities to be allotted or equity securities held as treasury shares to be sold after such expiry and the Directors may allot equity securities and/or sell equity securities held as treasury shares in pursuance of such an offer or agreement as if the power conferred by this resolution had not expired.

10. As an ordinary resolution:

That, subject to and conditional upon the admission of the New Ordinary Shares (as defined below) to trading on AIM becoming effective in accordance with section 618 of the Act, every 200 ordinary shares of £0.0025 each in the capital of the Company in issue at the close of business on 16 September 2022 (being the latest practicable date prior to the publication of this document) ("Existing Ordinary Shares") be and are hereby consolidated into one ordinary share of £0.50 ("New Ordinary Shares"), such New Ordinary Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the Existing Ordinary Shares as set out in the articles of association of the Company from time to time (the "Articles") provided that, where such consolidation results in any shareholder being entitled to a fraction of a New Ordinary Share, such fraction shall be dealt with by the Directors as they see fit pursuant to their powers available to them under the Articles.

11. As a special resolution:

That, the Articles be amended by the insertion of a new article 2.5 as follows:

"2.5 Whenever as a result of a consolidation, division or sub-division of shares any fractions arise, the board may settle the matter in any manner it deems fit and in particular may sell shares representing fractions to which any members would otherwise become entitled to any person (including, subject to the provisions of the Act, the Company) and distribute the proceeds of sale after deduction of the expenses of sale in due proportion among those members, except that if the amount due to a person is less than three pounds (£3) (or equivalent in any other currency) the sum may be retained for the benefit of the Company. Where certificated shares are to be sold, the board may authorise any person to execute an instrument of transfer of the shares to, or in accordance with the directions of, the purchaser. Where uncertificated shares are to be sold, the board may do all acts and things it considers necessary or expedient to effect the transfer of the shares to, or in accordance with the directions of, the purchaser. The transferee shall not be bound to see to the application of the purchase moneys nor shall his title to the shares be affected by any irregularity in or invalidity of the proceedings in relation to the sale."

20 September 2022

Registered office:

201 Temple Chambers
3-7 Temple Avenue
London
EC4Y 0DT

By order of the Board

Rory Shaw
Chairman

Explanatory Notes to the Notice of Annual General Meeting

References to the Company's issued share capital below are to the Company's issued ordinary share capital as at the close of business on 16 September 2022 (being the latest practicable date prior to the publication of this document). No shares are held in treasury.

The notes on the following pages give an explanation of the proposed resolutions. Resolutions 1-8 (inclusive) and 10 are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution. Resolution 9 is proposed as a special resolution. This means that for each resolution to be passed, at least three-quarters of the votes cast must be in favour of that resolution.

Resolution 1: Report and Accounts

The Directors are required to present to shareholders at the AGM the audited accounts of the Company for the financial period ended 31 May 2022 together with the Auditor's report and the Directors' report. Resolution 1 addresses this requirement.

Resolution 2: Directors' Remuneration Report

The Directors are seeking approval of the Directors' remuneration report, which is set out on pages 42 to 44 of the Company's Annual Report and Accounts, for the financial period ended 31 May 2022. This is an advisory vote and no entitlement to remuneration is conditional upon the resolution being passed.

Resolutions 3 to 4: Auditors and their Remuneration

Company law requires the Company, at each general meeting at which accounts are laid, to appoint auditors who will remain in office until the conclusion of the next general meeting at which accounts are laid. Price Bailey LLP has indicated its willingness to continue in office and Resolution 3 proposes to make this appointment.

Resolution 4 authorises the Directors to agree the Auditor's remuneration. It is normal practice for shareholders to resolve at the AGM that the Directors decide on the level of remuneration of the Auditors for the audit work to be carried out by them in the next financial year. The amount of remuneration paid to the Auditors for the next financial year will be disclosed in the next audited accounts.

Resolutions 5 to 7: Reappointment of Directors

All Directors of the Company must retire from office at the first Annual General Meeting at which they were appointed. Anesh Patel and Annemijn Eschauzier, having been appointed since the last Annual General Meeting of the Company, are accordingly offering themselves for election pursuant to Article 69 of the Company's articles of association.

Rory Shaw is retiring and offering himself for re-election by shareholders pursuant to Article 63 of the Company's articles of association.

Brief biographies of all Directors can be found in the Annual Report and Accounts for the year ended 31 May 2022 and on the Company's website <https://fbkmed.com/feedback-plc/team/>.

Resolution 8: Authority to Allot Shares

This resolution deals with the Directors' authority to allot ordinary shares in accordance with section 551 of the Companies Act 2006 (**the Act**). This resolution is to renew the authority given to the Directors to allot shares or rights to subscribe for or convert security into shares in the capital of the Company subject to the conditions of the Act. This resolution will, if passed, authorise the Directors to allot (or grant rights over) ordinary shares under an open offer, rights issue or in other situations, up to a maximum aggregate nominal amount of £2,220,221, which is equivalent to no more than 33.3% of the Company's issued share capital (which represents 888,088,248 shares of £0.0025 each).

As at the close of business on 16 September 2022, the Company did not hold any treasury shares.

The authority granted by this resolution will expire at the conclusion of the Company's next annual general meeting after the passing of this resolution or fifteen months after the date on which Resolution 8 is passed, whichever is the earlier. As of the date of this Notice the Company holds no treasury shares.

Resolution 9: Disapplication of Pre-emption Rights

Section 561 of the Act requires that a company issuing shares for cash must first offer them to existing shareholders following a statutory procedure which, in the case of a rights issue, may prove to be both costly and cumbersome. This special resolution excludes that statutory procedure as far as rights issues are concerned. It also enables the Directors to allot shares up to an aggregate nominal value of £666,733, which is equal to approximately 10% of the nominal value of the current share capital of the Company, without first offering them to existing shareholders in proportion to their existing holdings. The Directors believe that the powers provided by this resolution will maintain a desirable degree of flexibility.

Unless previously revoked or varied, the power granted by Resolution 9 will expire at the conclusion of the Company's next annual general meeting after the passing of this resolution or, if earlier, fifteen months after the passing of this resolution.

Resolutions 10 and 11: Share Consolidation and Amendment to the Articles of Association

The Company's current issued share capital totals over 2.6 billion ordinary shares of £0.0025 each.

The Directors believe that this capital structure impacts the Company's share price as the high number of Existing Ordinary Shares in issue combined with the relatively low price per share is thought to result in excess volatility, reduced liquidity and a widening in the market bid and ask share price spread in the Company's shares. In order to reduce the number of issued shares to a more appropriate number, the board of directors of the Company (the "Board") are proposing (through Resolution 10) a 200:1 share consolidation where the existing ordinary shares of £0.0025 ("Existing Ordinary Shares") are consolidated into new ordinary shares of £0.50 each ("Share Consolidation").

The effect of the Share Consolidation as proposed in Resolution 10 will be that shareholders holding Existing Ordinary Shares on the Company's register of members at 6:00 p.m. on 13 October 2022 (the 'Share Consolidation Date of Effect') will, on the implementation of the Share Consolidation, hold:

1 New Ordinary Share for every 200 Existing Ordinary Shares held on the Share Consolidation Date of Effect.

The Directors' consider that the Share Consolidation will result in a more appropriate share capital structure for the Company which is expected to:

- increase the Company's share price proportionately which may consequently positively impact the liquidity of and trading activity in the Company's shares;
- provide the basis for a potential narrowing of the bid and offer spread the Company's shares;
- provide the basis for enhanced perception of the Company and its prospects, improving its marketability to a wider investor group.

Accordingly, the Directors believe that the Share Consolidation is in the best interests of shareholders and is necessary in order to provide the Company with a suitable share capital structure that will facilitate future growth opportunities.

Proposed Capital Reorganisation

	Number of Ordinary Shares	Nominal Value
Current share capital	2,666,931,677	£6,667,329.19
Shares to be issued in consolidation process	123	£0.31
Share Capital following Consolidation	13,334,659	£6,667,329.50

Most shareholders will not hold at the Share Consolidation Date of Effect a number of Existing Ordinary Shares that is exactly divisible by the consolidation ratio described above. The result of the Share Consolidation, if approved, will be that such shareholders will be left with a fractional entitlement to a resulting New Ordinary Share. Any such fractions as a result of the Share Consolidation will be aggregated and, the Directors will to the extent empowered by the Company's articles of association sell the resulting shares in the market for the benefit of the relevant shareholders. The proceeds from the sale of the fractional entitlements shall be distributed pro rata amongst the relevant shareholders, save that if the proposed amendment to the Company's articles of association is approved where a Shareholder is entitled to an amount which is less than £3 it will be retained for the benefit of the Company.

As all shareholdings in the Company will be consolidated, the number of ordinary shares held by each shareholder will be reduced, but the percentage of the total issued ordinary share capital of the Company held by each shareholder immediately before and following the Share Consolidation will, save for fractional entitlements, remain unchanged.

Shareholders should be aware that any shareholder holding fewer than 200 Existing Ordinary Shares at the Share Consolidation Date of Effect will not receive any New Ordinary Shares and on completion of the Share Consolidation will no longer be a shareholder. The nominal value of the Company's ordinary shares will change from £0.0025 per share to £0.50 per share. Aside from having a different nominal value, each New Ordinary Share will carry the same rights as set out in the Company's articles of association that currently attach to the Existing Ordinary Shares. The Share Consolidation will not affect the Company's net assets, nor the net assets of the Group.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on the AIM Market in place of the Existing Ordinary Shares ("Admission"). Subject to Resolution 10 being passed, dealings in the Existing Ordinary Shares will cease on the Record Date and it is expected that admission will become effective and that dealings in the New Ordinary Shares will commence on 8.00am on 14 October 2022.

The Company expects that the current ISIN in relation to the Existing Ordinary Shares will be disabled and marked for expiry in CREST after market close on 13 October 2022. A new ISIN, GB00BJN59X09, in relation to the New Ordinary Shares is expected to come into effect at 8.00 a.m. on 14 October 2022.

It is expected that shareholders who hold Existing Ordinary Shares in uncertificated form will have their CREST accounts credited with their New Ordinary Shares at 8.00 a.m. on 14 October 2022.

New share certificates in respect of the New Ordinary Shares will be issued within 10 business days following the Share Consolidation and will be posted to those shareholders who, on the Share Consolidation Date of Effect, hold their Existing Ordinary Shares in certificated form. These will replace existing share certificates which should then be destroyed. Pending the receipt of new shares certificates, the transfer of New Ordinary Shares in certificated form will be certified against the register of members of the Company.

Resolution 10 must be passed in order for the Share Consolidation to proceed.

Fractional entitlements

The Share Consolidation will replace every 200 Existing Ordinary Shares with one New Ordinary Share. If an individual shareholding is not exactly divisible by 200, the shareholder in question will be left with a fractional entitlement. Any such fractions as a result of the Share Consolidation will be aggregated and, the Directors will to the extent empowered by the Company's articles of association sell the aggregated shares in the market for the benefit of the relevant shareholders. The proceeds from the sale of the fractional entitlements shall be distributed pro rata amongst the relevant shareholders, save that if the proposed amendment to the Company's articles of association is approved where a Shareholder is entitled to an amount which is less than £3 it will be retained for the benefit of the Company. For the purpose of implementing this proposal, any Director shall be authorised to execute one or more instrument(s) of transfer in respect of such fractions of New Ordinary Shares on behalf of the relevant shareholders, and to do all acts and things the Directors consider necessary or desirable to effect such transfer.

If resolution 10 is passed, the Directors would propose to issue an additional 123 Ordinary Shares (the "Additional Ordinary Shares") to enable the Share Consolidation to take place without "orphan shares". These Additional Ordinary Shares will be issued to Feedback Plc. Since these Additional Ordinary Shares will only represent an entitlement to a fraction of a New Ordinary Share, this fraction will be sold pursuant to the arrangements for fractional entitlements described above.

For the avoidance of doubt, the Company is only responsible for dealing with fractions arising on registered holdings. For shareholders whose shares are held in the nominee accounts of UK stockbrokers, the effect of the Share Consolidation on their individual shareholdings will be administered by the stockbroker or nominee in whose account the relevant shares are held. The effect is expected to be the same as for shareholdings registered in beneficial names, however it is the stockbroker's or nominee's responsibility to deal with fractions arising within their customer accounts, and not the Company's responsibility.

Effects of proposal

Following the Share Consolidation and assuming no further shares are issued between 16 September 2022, being the latest practicable date before the publication of this Notice of AGM, and the Share Consolidation Date of Effect, the Company's issued ordinary share capital is expected to comprise 13,334,659 New Ordinary Shares.

Recommendation

The Board of Feedback plc considers all of the proposed resolutions to be in the best interests of the Company and shareholders as a whole and, accordingly, recommends that shareholders vote in favour of all the resolutions proposed, as the Directors intend to do in respect of their own holdings.

Yours faithfully

Rory Shaw, Chairman

Notes to the Notice of Annual General Meeting

The following notes explain your general rights as a shareholder and your right to attend and vote at the Annual General Meeting (**AGM**) or to appoint someone else to vote on your behalf.

Any changes to the proposed format of the Annual General Meeting will be announced via RNS and outlined on the Company's website (<https://fbkmed.com/feedback-plc/announcements>)

1. Only holders of ordinary shares are entitled to attend and vote at the Annual General Meeting. A member is entitled to appoint another person as his proxy to exercise all or any of his rights to attend, to speak and vote at the meeting. A member may appoint more than one proxy in relation to the meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by the relevant member. A proxy need not be a member of the Company.
2. You can register your vote(s) for the meeting either:
 - By logging on to www.shareregistrars.uk.com, clicking on the "Proxy Vote" button and then following the on-screen instructions;
 - By post or by hand to Share Registrars Limited, 3 The Millennium Centre, Crosby Way, Farnham, Surrey GU9 7XX using the Form of Proxy accompanying this notice;
 - In the case of CREST members, by utilising the CREST electronic proxy appointment service in accordance with the procedures set out in note 5 below.

In order for a proxy appointment to be valid the proxy must be received by Share Registrars Limited by 11:00 a.m. on 11 October 2022, being 48 hours (ignoring any part of any day that is not a working day) before the start of the Annual General Meeting. Completion of a proxy voting instruction will not preclude members attending and voting in person at the Annual General Meeting, should they so wish.

3. In the case of joint shareholders, the signature of the senior shareholder (seniority to be determined by the order in which the names stand in the register of members) shall be accepted to the exclusion of all other joint holders. The names of all joint shareholders should be stated at the top of the form.
4. In order to have the right to attend and vote at the Annual General Meeting (and also for the purpose of determining how many votes a person entitled to attend and vote may cast), a person must be entered on the register of members of the Company at 11.00 a.m. on 11 October 2022, being 48 hours (ignoring any part of any day that is not a working day) before the start of the Annual General Meeting, or, in the event of any adjournment, 48 hours before the start of the adjourned meeting (ignoring any part of any day that is not a working day). Changes to entries on the register of members after this time shall be disregarded in determining the rights of any person to attend or vote at the Annual General Meeting.
5. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual (available via www.euroclear.com/CREST). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s) who will be able to take the appropriate action on their behalf.
6. In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear UK & Ireland Limited's ("Euroclear") specifications and must contain the information required for such instruction, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID 7RA36) by the latest time for the receipt of proxy appointments specified in paragraph 2 above. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

7. CREST members and, where applicable, their CREST sponsors, or voting service providers should note that Euroclear UK & Ireland does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will, therefore, apply in relation to the input of CREST proxy instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST 58 sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
8. The Company may treat as invalid a CREST proxy instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
9. Any corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of the powers as a member provided that no more than one corporate representative exercises powers over the same share.
10. Any member attending the Annual General Meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business dealt with at the Annual General Meeting but no such answer need be given if: (a) to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information; (b) the answer has already been given on a website in the form of an answer to a question; or (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.
11. As at 16 September 2022 (being the last Business Day prior to the publication of this Notice), the Company's issued ordinary share capital consisted of 2,666,931,677 Ordinary Shares, carrying one vote each. Therefore, the total voting rights in the Company as at 16 September 2022 were 2,666,931,677.
12. A copy of this Notice, and other information required by section 311A of the Act, can be found at <https://fbkmed.com/feedback-plc/aim-rule-26/>.
13. You may not use any electronic address (within the meaning of section 333(4) of the Act) provided in this Notice or in any related documents (including the Chairman's letter and Form of Proxy) to communicate with the Company for any purposes other than those expressly stated.
14. Your personal data includes all data provided by you, or on your behalf, which relates to you as a shareholder, including your name and contact details, the votes you cast and your Reference Number (attributed to you by the Company). The Company determines the purposes for which and the manner in which your personal data is to be processed. The Company and any third party to which it discloses the data (including the Company's registrars) may process your personal data for the purposes of compiling and updating the Company's records, fulfilling its legal obligations and processing the shareholder rights you exercise.